Avalo Therapeutics (AVTX) Corporate presentation summary

Strategic focus and pipeline

• Advancing a pipeline of novel IL-1β therapies targeting unmet medical needs in immune-mediated inflammatory diseases.

• Lead asset abdakibart (AVTX-009) is positioned for best-in-class efficacy in hidradenitis suppurativa (HS) and other inflammatory conditions.

• Scientific rationale supports expansion into additional IL-1β-driven diseases, including arthritis and inflammatory bowel disease.

Lead asset: abdakibart (AVTX-009)

• Abdakibart is a high-affinity, IL-1β-specific monoclonal antibody with a longer half-life and higher bioavailability than lutikizumab.

• Demonstrated rapid and significant reduction of inflammatory biomarkers and favorable safety in clinical trials.

• Phase 2 LOTUS trial in HS completed enrollment; topline data expected Q2 2026.

• Potential for less frequent dosing and higher efficacy due to pharmacological advantages.

Market opportunity and disease landscape

• HS is a chronic, debilitating inflammatory skin disease with significant unmet need due to limited efficacy of current anti-TNF and anti-IL-17 therapies.

• HS market projected to exceed $10B globally by 2035, driven by increased diagnosis, treatment, and biologic adoption.

• Moderate-to-severe HS population in the US expected to grow from 1.0M in 2024 to 1.6M by 2035.